scholarly article | Q13442814 |
P50 | author | Andreas Plückthun | Q23057697 |
P2093 | author name string | Jung S | |
P433 | issue | 8 | |
P921 | main subject | antibody | Q79460 |
P304 | page(s) | 959-966 | |
P577 | publication date | 1997-08-01 | |
P1433 | published in | Protein Engineering Design and Selection | Q15762396 |
P1476 | title | Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting | |
P478 | volume | 10 |
Q33307001 | A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm |
Q33224274 | A mutation designed to alter crystal packing permits structural analysis of a tight-binding fluorescein-scFv complex |
Q30810608 | An alternating selection strategy for cloning phage display antibodies |
Q56891850 | An integrated approach to extreme thermostabilization and affinity maturation of an antibody |
Q47937927 | An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly |
Q39016494 | Antibody Fragments as Probe in Biosensor Development |
Q56896775 | Antibody engineering |
Q39793519 | Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts |
Q43052895 | Characterization of the 4D5Flu single-chain antibody with a stimulus-responsive elastin-like peptide linker: a potential reporter of peptide linker conformation |
Q57840014 | Characterizing the functionality of recombinant T-cell receptors in vitro: a pMHC tetramer based approach |
Q47158894 | Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv. |
Q38323531 | Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor |
Q33789036 | Conversion of scFv peptide-binding specificity for crystal chaperone development |
Q30406181 | Crystallization chaperone strategies for membrane proteins |
Q90212096 | Design and Production of Bispecific Antibodies |
Q33283622 | Design of synthetic antibody libraries |
Q34630307 | Designing immunotoxins for cancer therapy. |
Q30845963 | Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework |
Q30923970 | Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity |
Q40176311 | Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. |
Q51246263 | Engineering Antibodies for Biosensor Technologies. |
Q47613006 | Engineering stable cytoplasmic intrabodies with designed specificity |
Q36130655 | Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection |
Q53627592 | Enhanced stabilization of a stable single domain antibody for SEB toxin by random mutagenesis and stringent selection. |
Q33659675 | Exploiting antibody-based technologies to manage environmental pollution |
Q34983046 | Expression and folding of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm |
Q90668587 | Expression of anti-tumor recombinant IgG- and IgE-like genes in eukaryotic cells |
Q40903643 | Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. |
Q43887450 | Forces and energetics of hapten-antibody dissociation: a biased molecular dynamics simulation study |
Q78454268 | Functional improvement of antibody fragments using a novel phage coat protein III fusion system |
Q79182590 | Generation of a highly stable, internalizing anti‐CD22 single‐chain Fv fragment for targeting non‐Hodgkin's lymphoma |
Q35748485 | Increased Fab thermoresistance via VH-targeted directed evolution |
Q27636955 | Increasing protein stability by polar surface residues: domain-wide consequences of interactions within a loop |
Q26740106 | Intracellular targeting with engineered proteins |
Q30944840 | Methods for generating multivalent and bispecific antibody fragments |
Q33518649 | Oligovalent Fab display on M13 phage improved by directed evolution |
Q30712277 | Phage versus phagemid libraries for generation of human monoclonal antibodies. |
Q30155518 | Probing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation study |
Q35024068 | Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line |
Q42854245 | Rational engineering of antibody therapeutics targeting multiple oncogene pathways |
Q40196625 | Role of native-state topology in the stabilization of intracellular antibodies |
Q38332125 | Selecting proteins with improved stability by a phage-based method |
Q32066800 | Selection for a periplasmic factor improving phage display and functional periplasmic expression |
Q33249034 | Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display |
Q36639059 | Single-domain antibody fragments with high conformational stability |
Q35764163 | Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach |
Q26859495 | Stability engineering of the human antibody repertoire |
Q41609499 | Structure-based design of supercharged, highly thermoresistant antibodies |
Q42662047 | The Skp chaperone helps fold soluble proteins in vitro by inhibiting aggregation. |
Q56038596 | The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies |
Q30854397 | The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA. I. Increased functional expression of antibody fragments with and without cis-prolines. |
Q33586057 | The selection of intracellular antibodies. |
Q37392835 | Unbinding forces of single antibody-antigen complexes correlate with their thermal dissociation rates |
Q34045831 | Versatile strategy for controlling the specificity and activity of engineered T cells |
Search more.